Calcium clodronate

Drug Profile

Calcium clodronate

Latest Information Update: 19 Sep 2000

Price : $50

At a glance

  • Originator Leiras Oy
  • Developer Leiras Oy; Nonindustrial source
  • Class Antirheumatics; Bisphosphonates; Calcium regulators; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bone disorders; Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2000 No-Development-Reported for Bone disorders in Scandinavia (PO)
  • 19 Sep 2000 No-Development-Reported for Rheumatoid arthritis in Finland (IM)
  • 29 Jun 1998 A case report of a patient with Gorham's disease has been added to the Musculoskeletal therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top